Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Biodexa Pharmaceuticals Says We Have The Resources To Deliver Two Sets Of Preclinical Data And Three Sets Of Clinical Data In 2024; Our Development Pipeline Now Includes Five Programs, Of Which Four Are At Clinical Stage; With Pipeline Stronger Than It Has Ever Been, We Are Enthusiastic About The Potential For Our Company In 2024 And Beyond.

Author: Benzinga Newsdesk | April 19, 2024 08:09am

Posted In: BDRX